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Research in context 
Evidence before this study 
Ovid databases (MEDLINE, Embase, PsychINFO) were searched for articles relating to 
health-related quality of life (HRQL) and “localised”, “advanced”, “metastatic”, “stage” and 
“prostate cancer” or “prostatic neoplasms” up to June 2018.  Most articles relate to men with 
localised disease, with good quality evidence collected in the setting of clinical trials and 
observational studies of specific cohorts.  Few studies have focused on those diagnosed with 
locally advanced or metastatic prostate cancer (PCa).  In the small number of studies 
separating results by stage, poorer HRQL has been associated with later stage of disease.  
However, sample sizes tend to be small.  Therefore, little is known about the impacts of PCa 
in men living with and beyond a diagnosis of advanced disease, especially in comparison to 
men with non-metastatic disease. 
Added value of the study 
This is first study able to compare, at scale, the HRQL and functional outcomes of men living 
with localised and advanced PCa.  Data were collected on 35,823 men, with diagnostic stage 
available on 30,733 of whom 23.4% had stage III disease and 12.8% stage IV.  The 
population-based approach enables true definition of the quality of survival of the increasingly 
prevalent group of men living with and beyond PCa.  We identified that men with stage III and 
IV disease reported more problems, including those generic to health and those related to 
treatment, particularly androgen deprivation therapy (ADT).  Poor sexual function was 
reported by most men, regardless of stage, and the majority (56.5%) reported not being 
offered any intervention or support for this.  Despite specific functional morbidities, many men 
with PCa self-reported their overall health to be similar to men in general population studies 
and a substantial proportion of men with stage IV disease (23.5%) reported no problems on 
any EQ-5D dimension.  These results highlight areas of unmet need and will be vital in helping 
men make informed decisions about their treatment. 
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Implications of all the available evidence 
Most men living 18-42 months after a diagnosis of PCa can expect to experience as good 
HRQL as men in the general population, including those with stage III and a substantial 
proportion of those with stage IV disease.  Although significant sexual morbidity is common, 
the majority of men are not offered helpful intervention or support.  The evidence suggests 
that there are subgroups of men who would benefit from service improvements around sexual 
rehabilitation and measures to minimise the use of ADT.  These include wider use of 
intermittent ADT (versus continuous use), the avoidance of unnecessary ADT (i.e. for non-
metastatic disease) and the use of shorter neoadjuvant courses (reduced from 3 years to 1 
year).  This study collected data from men living up to a maximum of 42 months beyond 
diagnosis.  Those with stage IV disease are likely to experience deterioration in their HRQL at 
some point following this.  Further evidence is needed to inform appropriate service provision 
for them in these later years. 
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Abstract 
 
Background: Little is known about the health-related quality of life (HRQL) of men living with 
advanced prostate cancer.  We report for the first time population-wide functional outcomes 
and HRQL in men with advanced or localised disease. 
Methods: Men diagnosed 18-42 months previously were identified across the United 
Kingdom. Functional outcomes (EPIC-26 plus interventions for sexual dysfunction) and 
generic HRQL (EQ-5D-5L & self-assessed health) were assessed through a postal survey. 
Diagnostic stage was obtained through cancer registration records and treatment was self-
reported. 
Findings: 35,823 (60.8%) men responded.  Stage was known for 85.8%; 19,599 (63.8%) 
stage I/II, 7,209 (23.4%) stage III, 3,925 (12.8%) stage IV.  Men with stage III and IV disease 
reported more problems, including those generic to health and those related to treatment.  
Poor sexual function was common (81.0%), regardless of stage.  Over half of men (56.5%) 
received no intervention for this.  Differences in urinary and bowel morbidity were greater with 
respect to treatment than stage.  Androgen deprivation therapy (ADT) was associated with 
poorer HRQL, hot flushes, weight gain and lack of energy.  Overall self-assessed health was 
similar in men with stage I-III disease, and whilst reduced in those with stage IV cancer, 23.5% 
with metastatic disease reported no problems on any EQ-5D dimension.   
Interpretation: Men diagnosed with advanced disease do not report markedly different HRQL 
outcomes to those diagnosed with localised disease, although significant problems with 
hormonal function and fatigue are reported amongst men treated with ADT.  Sexual 
dysfunction is common and the majority of men are not offered helpful intervention or support.  
Service improvements around sexual rehabilitation and measures to reduce the impact of ADT 
are required.   
Funding: Movember Foundation, in partnership with Prostate Cancer UK, as part of the 
Prostate Cancer Outcomes programme, grant number BO26/MO.  
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Background  
The number of prostate cancer (PCa) survivors has increased rapidly over recent decades.  
According to population-based cancer registry data, 10-year survival has tripled in the last 40 
years in the United Kingdom (UK)1.  In England, there are an estimated 325,000 men alive 
having been diagnosed with PCa between 1995 and 20152.  A principal challenge for 
healthcare is to understand the needs of this growing group of men, in particular the problems 
and challenges faced by those living with advanced disease (30% of men with distant 
metastases now survive at least five years3).  The quality of survival experienced, with 
definition of the specific impacts of the disease and its treatment, must be robustly determined 
to facilitate appropriate care provision4.  
Significant sexual, urinary and bowel morbidities have been identified following treatment of 
localised PCa, with the pattern and severity of morbidity varying according to the type and 
intensity of treatment received5-8.  Most intelligence originates from randomised controlled 
trials and observational studies of specific cohorts, often reporting outcomes following surgery 
compared to radiotherapy and surveillance in men with localised PCa9.  Evidence for the UK 
has not been generated at an unselected population level.  In addition, few studies have 
reported outcomes in men with locally advanced or metastatic disease.  Such studies tend to 
be small and are mostly clinical trials comparing specific treatment types10-12.   
The Life After Prostate Cancer Diagnosis (LAPCD) study adopts an established approach to 
the measurement of population-level health-related quality of life (HRQL), previously used in 
a national population of colorectal cancer survivors13, and extends this to men living with all 
stages of PCa 18-42 months post diagnosis.  An internationally recommended series of 
outcome measures has been utilised to facilitate comparison and interpretation, with specific 
enquiry as to the impact of interventions offered for sexual dysfunction14.  Here we report the 
functional outcomes (urinary, bowel, sexual and vitality/hormonal) and HRQL of men with PCa, 
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in order to a) quantify and compare outcomes across all disease stages and treatment groups, 
and b) identify implications for healthcare delivery. 
Methods 
The LAPCD methodology has been reported in full15 but is outlined below. 
Participants 
All National Health Service (NHS) Hospital Trusts/Health Boards treating PCa were 
approached.  In England, 111 of 136 Trusts participated; 21 declined and 4 were involved in 
overlapping studies (Supplementary figure 1).  All Trusts/Health Boards in Northern Ireland 
(NI; n=5), Scotland (n=14) and Wales (n=6) participated.  Men alive 18-42 months after a PCa 
diagnosis (ICD1016 C61) in participating Trusts/Boards were identified from national 
population-based cancer registries in England, NI and Wales.  In Scotland, due to privacy 
restrictions, men were identified through hospital activity data and verified through the cancer 
registry.  Approximately 82% of eligible men with PCa across the UK were invited to 
participate.     
Data collection 
Men were sent a postal survey (Supplementary file 1) from their treating Trust/Board.  Men 
consented by returning completed surveys and declined by not returning them, returning them 
unanswered or opting out via a free-phone helpline.  Up to two reminders were sent to non-
responders.   
Functional outcomes and HRQL were assessed using the items defined in the International 
Consortium on Health Outcome Measurement (ICHOM) minimum outcome dataset14: the 
Expanded Prostate cancer Index Composite short form (EPIC-26)17; items on use of 
interventions to improve sexual function; and EQ-5D-5L18.  The survey included other 
measures covering social difficulties, decision regret, emotional well-being and others, which 
will be reported elsewhere.   
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Patient involvement 
A User Advisory Group, including 6 PCa survivors, was chaired by HB (co-investigator and 
PCa survivor).  The group has been involved in all stages of the study from design through to 
interpretation and dissemination of results.  
Data handling 
Stage at diagnosis was obtained from national cancer registration records.  Stage I and II were 
combined into a ‘localised disease’ group and compared to stage III and IV separately.  An 
area-based measure of socio-economic deprivation (split into quintiles) was derived using 
postcode of residence19-22.  Age, presence of other long-term conditions and treatments 
received were derived from the survey data.  Age (question 78) was categorised as <55, 55-
64, 65-74, 75-84, and ≥85 years.  Where missing, this was supplemented by cancer 
registration data (accounting for the lag between diagnosis and survey).  Other long-term 
conditions (question 84) were counted and categorised as none, 1, 2, 3, ≥4.  Treatments 
(question 8) were categorised into single therapies (e.g. surgery alone or external beam 
radiotherapy [EBRT] alone) or combinations therapies (e.g. EBRT and androgen deprivation 
therapy [ADT]) (Supplementary file 2).   
EPIC-26 measures function across five domains (urinary incontinence, urinary irritation and 
obstruction, bowel, sexual, vitality/hormone), using 26 items.  Domain scores range from 0-
100, with 100 representing best possible function.  Where one item in a domain was missing, 
this was substituted with the mean of the available items, as per the scoring guidance23.  In 
addition to mean scores, individual item responses were used to derive the proportion 
reporting a moderate/big problem (or equivalent), as per Watson et al24. 
The ICHOM dataset includes two items assessing use of medications and devices for erectile 
dysfunction25.  These were amended to avoid drug/trade names (Supplementary file 1, 
questions 25-26).  An extra item on use of specialist services to help with sex life was included 
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(Supplementary file 1, question 27).  The possible response categories were grouped as ‘not 
offered’, ‘offered but did not want/try it’, ‘offered but did not help’, ‘offered and it helped’.  
EQ-5D-5L records information on five dimensions (mobility, self-care, usual activities, 
pain/discomfort, anxiety/depression), plus a rating of self-assessed health (SAH) based on 
“how good or bad your health is today” (valued 0-100, where 100 represents best possible 
health).  The proportion of respondents reporting any problem, regardless of severity, in each 
dimension separately and across all five dimensions was derived.  Mean SAH ratings were 
calculated. 
Statistical analysis 
Log-linear regression was used to model the continuous outcomes (EPIC-26 functional 
domain scores and the EQ-5D SAH score), as this approach provided a better fit to the data 
than a linear one.  Binary logistic regression models were developed for each individual EPIC-
26 item (with moderate/big problems, or equivalent, as the outcome) and each EQ-5D 
dimension (with reporting of any problem as the outcome).  To generate results by stage and 
treatment, these variables were added separately to the models.  Each model included 
adjustment for age (as a linear term), socio-economic deprivation and number of other long-
term conditions.  Subgroup analyses by age group were adjusted for socio-economic 
deprivation and other long-term conditions.  Resulting model coefficients were used to predict 
the mean scores and proportions for each stage and treatment group, taking account of the 
different case-mix profiles of each group.  Analysis of the use of interventions for sexual 
dysfunction was based on the raw survey responses, in order to reflect ‘real world’ provision 
of sexual support to men with prostate cancer.  In all analyses, men with missing responses 
were excluded on a question-by-question basis, thus all proportions and mean values refer to 
the men who responded to that question.  Due to the large number of men included in the 
study, statistical significance can be achieved with only small differences in outcomes, and 
these may not be clinically relevant.  As such, results are presented alongside previously 
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estimated minimally important differences (MIDs), where available26-28.  Analyses were 
performed using Stata version 15.0 (StataCorp, TX, USA).  
Role of the funding source 
The funders of the LAPCD study had no role in the design of the study, the data collection, 
analysis and interpretation, the writing of the manuscript or the decision to submit for 
publication.  Anonymised study data were available to AD and SW. The corresponding author 
had full access to the anonymised data and had final responsibility to submit the article for 
publication.   
Results 
Sample size and response rates 
Initially, 59,990 eligible men were identified; 1,060 (1.8%) died during the study period, giving 
a final sample of 58,930.  Of these, 35,823 returned completed questionnaires (60.8% 
response) (Supplementary figure 1).  Men aged under 55 (51.8% response) or over 85 (36.9% 
response), from non-white ethnic groups (38.0% response) and those living in the most socio-
economically deprived areas (48.3% response) were less likely to participate (Supplementary 
table 1).  By stage, response rates were highest in the men diagnosed with stage III cancer 
(65.7%) and lowest in those diagnosed with stage IV disease (58.1%). Within the completed 
questionnaires, levels of missing data were generally low e.g. <3% missing for EQ-5D 
(Supplementary table 2).  EPIC-26 items were less well completed and domain scores could 
not be calculated in 9-18% of cases.  Completion was highest for the sexual function domain 
and lowest for the urinary irritation domain.  
Characteristics of the population 
Nearly half (46.4%) of the cohort were aged 65-74 at survey (median 71 years, IQR 67-77) 
(Table 1).  A quarter (26.3%) of the men lived in the least socio-economically deprived areas 
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and 10.1% lived in the most deprived.  Most men (71.0%) reported at least one other long-
term condition, with 7.2% reporting four or more.   
Stage at diagnosis was known for 85.8% (30,733) of respondents, of whom 63.8% (19,599) 
had stage I or II disease, 23.4% (7,209) stage III, and 12.8% (3,925) stage IV.  Table 1 details 
the characteristics of each stage group, including those with unknown stage.  The men 
diagnosed with stage IV disease (median age 73 years, IQR 68-79) were older than those 
with stage I/II disease (median age 71 years, IQR 66-76).  The median age of the group with 
unknown stage was 73 (IQR 67-79).  The socio-economic deprivation and long-term condition 
profiles were similar across the known stage groups, whilst a higher proportion of the group 
with unknown stage lived in the least socio-economically deprived areas (p<0.001).    
The treatments reported by the men are detailed in Table 1. Across the whole cohort, 20.9% 
reported receiving combined EBRT and ADT, with a further 19.7% reporting having surgery 
alone (Table 1).  Of those diagnosed with stage I/II disease, 20.3% reported being on a 
monitoring regime (active surveillance (AS) or watchful waiting) and 23.5% reported having 
surgery alone.  Most men diagnosed with stage IV cancer were receiving ADT, either alone 
(28.4%) or in combination with EBRT and/or other systemic therapy (chemotherapy, 
Abiraterone, Enzalutamide) (40.7%).   
Specific functional outcomes 
EPIC-26 domain scores 
Mean adjusted EPIC-26 domain scores were high, indicating good function, except for sexual 
function where scores were much lower (24.0) (Table 2).  Urinary and bowel function were 
similar across all disease stages (<3 point difference), whereas vitality/hormone and sexual 
function were substantially reduced in men with stage III and IV PCa compared to those with 
localised disease (8-16 point difference for hormone function and 12-17 point difference for 
sexual function).  Men treated surgically reported more urinary incontinence, whilst those on 
ADT reported worse hormonal and sexual function.     
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Urinary function 
Needing to urinate frequently was the most common urinary symptom (adjusted proportion: 
18.6% reported a moderate/big problem), followed by leaking at least once per day (adjusted 
proportion: 12.7%).  There were only small differences in the reporting of urinary symptoms 
by stage (Figure 1a).  Men who underwent surgery reported high levels of urinary incontinence 
(adjusted proportions: 23.4% leaked at least once per day and 31.4% used one or more pads 
per day in the surgery alone group) (Supplementary table 3).  Problems with urinary frequency 
and weak stream/incomplete emptying were less of a problem in the ‘surgery alone’ group 
than in other treatment groups.    
Bowel function 
Problems with bowel function were relatively infrequent compared to other domains and varied 
little by stage of disease (Figure 1a).  Bowel urgency was the most common bowel problem 
(adjusted proportion: 8.8% reported a moderate/big problem).  Bowel problems were more 
frequent following EBRT, alone or in combination.  For example, 11.4% of the ‘EBRT alone’ 
group reported moderate/big problems with bowel urgency compared to 4.4% in the ‘surgery 
alone’ group (adjusted proportions: Supplementary table 3). 
Vitality/hormone function 
Problems with lack of energy, hot flushes and weight gain were most commonly reported 
(Supplementary table 3).  There were much larger differences in the reporting of these 
symptoms by stage than was seen for urinary and bowel function (Figure 1a), however, this is 
related to the treatment received.  Men treated with ADT, alone or in combination with other 
therapy, reported much higher rates of problems with hormonal function and fatigue.  For 
example, 30.7% of men treated with ADT reported moderate/big problems with hot flushes 
(compared to 5.4% in the no-ADT group) and 29.4% of men treated with ADT reported 
problems with lack of energy (compared to 14.7% in the no-ADT group) (Figure 1b).  There 
was a smaller difference in the reporting of depression between the ADT and no-ADT groups 
(11.4% and 6.6% reporting moderate/big problems). 
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Sexual function 
Problems with sexual function were more common than issues in other domains: poor/very 
poor erections (81.5%), poor/very poor ability to reach orgasm (76.6%) and poor/very poor 
overall sexual function (81.0%) (adjusted proportions: Supplementary table 3).  In men with 
localised disease, 75.0% reported poor/very poor sexual function, as did 90.4% of men with 
stage III and 96.0% of men with stage IV cancer (adjusted proportions: Figure 2a).  By 
treatment, just over half of men on AS (51.1%) reported poor/very poor overall sexual function, 
increasing to 83.7% of men who had surgery alone and 93.6% receiving ADT alone (adjusted 
proportions: Supplementary table 3).   
Looking across the age groups, just over half (54.5%) of the men aged <55 reported poor/very 
poor sexual function and this increased sharply with age (Figure 2b).  A substantial proportion 
of men (45.2% overall) perceived their (lack of) sexual function to be a moderate/big problem; 
however, this decreased slightly with age.    
Use of interventions to improve sexual function 
Across the cohort, 41.4% reported being offered medications to aid or improve erections, 
22.6% were offered devices to aid erections and 14.8% were offered specialist services to 
help with sex life (Supplementary table 4).  Over half (56.5%) were not offered any of these 
interventions.  Younger men were more likely to report having been offered intervention: 
however, even in the youngest age group (<55 years), 23.5% were not offered medications, 
48.9% were not offered devices and 76.0% were not offered access to specialist services 
(Figure 3).  By stage, similar proportions of men with stage I/II (46.7%) and stage III (47.7%) 
disease were offered interventions compared to 26.9% with stage IV (not shown). 
Amongst men offered any of the three interventions, 37.2% did not want them or did not try 
them, 23.8% found they did not help, and 39.0% reported at least one of them being helpful 
(Supplementary table 4).  Of those offered medications, 34.2% reported them being helpful.  
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Of those offered devices, 28.3% reported them as helpful.  For those offered specialist 
services, 18.9% found them helpful.   
Health-related quality of life 
The overall mean adjusted SAH score was 76.3 (Table 2).  SAH was 5.7 points lower in men 
with stage IV disease compared to men with localised cancer (mean adjusted scores: 71.7 
and 77.4 respectively).  Men with stage III disease reported a mean adjusted SAH score of 
76.3.  When looking across the age groups, the difference in SAH between stage I/II and stage 
IV was greater in the younger men (Figure 4a). A similar pattern was seen when looking at 
the effect of ADT use by age (Figure 4b).  
Respondents were most likely to report problems (of any level) with ‘pain/discomfort’ (41.7%) 
and least likely to report problems with ‘self-care’ (11.5%) (adjusted proportions: Table 
2).  Men with stage IV cancer reported more problems in each dimension, and this was highest 
for ‘pain/discomfort’ (54.6%) and ‘usual activities’ (53.3%).  Nearly a quarter (23.5%) of those 
with stage IV PCa reported no problems in any EQ-5D dimension (compared to 40.2% stage 
I/II and 35.3% stage III).  In the stage IV group, mean adjusted SAH was 85.1 in the men 
reporting no problems and 67.3 in those who reported ≥1 problem. 
Discussion  
This population-based study of functional outcomes and HRQL of over 30,000 men living 18-
42 months beyond PCa diagnosis represents the largest patient-reported outcome series to 
date.  It includes 11,000 men living with locally advanced or metastatic disease, an 
increasingly prevalent cohort of cancer survivors, frequently excluded from study.  The data 
show that the majority of men with stage III disease and approximately 25% of those with 
stage IV disease report good overall HRQL.  However, sexual morbidity is high, irrespective 
of stage of disease, and over half of men reported they had not been offered intervention to 
help with this.  More than other treatments, ADT is associated with reduced overall HRQL.   
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Function 
Approaching 80% of the cohort reported poor or very poor sexual function and this was 
consistently high across the disease stages.  A recent study of older men in the general 
population found that 48% reported poor sexual function29.  In this study, 51% of men on active 
surveillance reported poor sexual function.  Sexual issues in these men are unlikely to be 
related to the diagnosis of PCa as they have not received any active treatment.  Hence, whilst 
sexual dysfunction is common in the general population, the levels reported by men treated 
for PCa are considerably higher.  Overall, 57% reported not being offered access to 
medications, devices or specialist services to address this, and only 40% of those offered help 
found it to be beneficial.  The extent of failure to receive support has not previously been 
described.  This intelligence would suggest clinical services need to proactively address this 
and ensure that sexual support is routinely offered to all men.  However, it must be 
acknowledged that not all men see their lack of sexual function as a problem and some will 
not want intervention to address this.  In particular, these data suggest that older men see 
their lack of sexual function as less of a problem than younger men.   
Overall levels of urinary and bowel problems in men with PCa are relatively low; however, 
there are subgroups with increased levels of dysfunction.  For example, men treated surgically 
reported higher levels of urinary incontinence with 30% reporting using pads daily, a finding 
which supports previous research5,8.  These men are between 18 and 42 months post-
diagnosis and there may be some recovery in function with longer follow-up5.   
In general, those with stage III and IV disease reported a higher level of problems, but in many 
cases these differences were small and were less than previously estimated MIDs for urinary 
and bowel function28.  Larger impacts on sexual function, hormonal function, fatigue and 
depression were seen and will, in part, be driven by treatment with ADT.  The majority of men 
with stage III or IV PCa will be on long-term or indefinite ADT.  There may be some recovery 
in those who stop ADT, with a corresponding reduction in symptoms, but testosterone levels 
may never recover to pre-treatment levels.  Longer-term follow-up of men would be required 
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to assess recovery of sexual function, levels of fatigue and other ADT-related effects.  The 
results suggest that clinicians should pursue treatment approaches that preserve testosterone 
function when possible and minimise ADT use.  Steps to reduce ADT-related morbidity might 
include wider use of intermittent ADT (versus continuous use), the avoidance of unnecessary 
ADT (i.e. for non-metastatic disease) and the use of shorter neoadjuvant courses (reduced 
from 3 years to 1 year).   
Health-related quality of life 
Despite significant sexual dysfunction, urinary difficulties and hormonal issues in some 
groups, this cohort of men living with and beyond the diagnosis of PCa report similar SAH to 
men in the general population29,30 (Table 3).  Differences in SAH amongst the overall LAPCD 
and general population samples are small, less than 3 points, with minimally important 
differences in EQ-5D SAH ratings having previously been estimated at being in the region of 
7 points26,27.  This apparent “resilience” of men with PCa may be accounted for by the “Gap 
Hypothesis” of quality of life, with the diagnosis of a life-threatening illness and subsequent 
experience of undergoing treatment leading to re-calibration of expectations and values31. 
This study is the first at-scale attempt to describe the outcomes of men living with locally 
advanced and metastatic PCa.  Overall the SAH of men with stage III disease is not markedly 
different from those with localised disease or UK general population surveys.  Whilst scores 
from those with stage IV disease are 6 points lower than those with localised disease, this 
may not equate to a clinically meaningful difference.  A quarter of men with stage IV PCa 
report no problems in any EQ-5D domain.  Not all men with Stage IV PCa experience similar 
clinical trajectories, with some living for prolonged periods and others living significantly 
shorter periods from diagnosis.  Sub-groups of men, such those with oligometastatic disease, 
may experience few problems whilst others experience diminished HRQL.  This study did not 
capture the detailed clinical information needed to investigate subtypes of disease.  The 
absence of other at-scale studies of the outcomes of men living with stage III and IV disease 
prevent comparison with other studies.  Further investigation into the outcomes of men living 
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with metastatic disease is required, particularly over a longer time period, as many will only 
develop symptoms a number of years after diagnosis. 
Strengths 
Through whole population sampling, potential recruitment or clinical trial intervention bias has 
been avoided.  In addition, all disease stages and treatments have been included, adding 
important new data on men living with and beyond diagnoses of advanced disease who have 
been largely omitted from previous quality of life outcome studies.  Utilisation of a standardised 
set of accepted outcome measures enables future international benchmarking. 
Data collection at this scale, from all centres in NI, Scotland and Wales and 111 of 136 NHS 
Trusts in England, has allowed us to produce datasets for individual Trusts, Cancer Alliances 
and regional health boards.  Internet-based tools will be made available to support service 
improvement, and in parallel, a public-facing electronic tool will provide an information and 
decision-making resource for men and their families, through identification of expected 
outcomes based on robust unselected data.  
Limitations 
The response rate of 61% is comparable to a similar survey of colorectal cancer survivors in 
England (63%)13.  Comparison of rates with other PCa trials and cohort studies is difficult due 
to different identification and recruitment methods.  Our response rate is reported without 
exclusion or screening of eligible individuals.  Non-respondents were more likely to be older, 
Black, Asian or minority ethnic and live in more socio-economically deprived areas.  These 
are groups who may be expected to potentially experience poorer HRQL.  Variation in 
response rate by stage was identified, with those with stage III disease having the highest 
response rates and those with stage IV disease at diagnosis the lowest.  We do not know if 
patients with worse health status were less likely to respond.  Data completeness was high for 
the majority of questions. Records with missing data were excluded from analysis, which 
assumes that those who did not respond to the question have similar outcomes to those who 
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did.  This assumption cannot be validated using the available data.  Men were less likely to 
avoid questions on sexual function than they were for some of the other domains, which is 
perhaps counter-intuitive but could indicate a real concern in this otherwise healthy-feeling 
group. 
Staging information was taken from national cancer registration data at diagnosis and was 
available for 86% of respondents.  The cancer registry uses a variety of data sources, including 
pathology reports and treatment databases, to capture stage information.  Some groups of 
men are less likely to appear in a treatment or pathology dataset near the time of diagnosis 
(for instance, those on watchful waiting are less likely to have a biopsy).  At the time when 
men in this study were diagnosed, there was less access to multi-disciplinary team systems 
to capture staging information, though this has now improved.  Treatment information was 
self-reported, due to limited data in cancer registries on types of monitoring and difficulties in 
capturing hormone therapies administered through primary care prescriptions (Public Health 
England, Personal Communication).  However, some respondents had difficulty reporting the 
treatments they received (e.g. distinguishing between types of radiotherapy) and these groups 
had to be excluded from some analyses. 
Conclusions 
Most men living 18-42 months after diagnosis of PCa can expect to experience as good HRQL 
as men in the general population.  Those diagnosed with locally advanced and metastatic 
disease do not report markedly different HRQL outcomes to those diagnosed with localised 
disease, although significant problems with hormonal function and fatigue are reported as a 
result of ADT.  However, it should be recognised that this study covers a limited window of 
time and HRQL in those with metastatic disease may deteriorate over a longer time period.  
Sexual dysfunction is common across all disease stages, with notably poor provision of sexual 
support.  Our results suggest that there are subgroups of men who would benefit from service 
improvements around sexual rehabilitation and measures to reduce the impact of ADT.  This 
study shows that outcomes for men with PCa are more strongly linked with the treatments 
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received than disease stage itself, although clearly the two are intertwined.  These results 
allow clinicians to present very positive goals for quality of survival 18-42 months after 
diagnosis, including for a substantial proportion of men with metastatic disease.  
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Table 1: Characteristics of the study sample split by stage at diagnosis 
    All men Stage I/II Stage III Stage IV Stage unknown 
    n % n % n % n % n % 
Total   35,823 100.0 19,599 54.7 7,209 20.1 3,925 11.0 5,090 14.2 
Treatment 
Active surveillance 2,928 8.2 2,320 11.8 0 0.0 0 0.0 457 9.0 
Watchful waiting 2,292 6.4 1,666 8.5 182 2.5 164 4.2 993 19.5 
Brachytherapy alone 1,208 3.4 940 4.8 62 0.9 13 0.3 294 5.8 
Surgery alone 7,054 19.7 4,606 23.5 1,323 18.4 132 3.4 193 3.8 
Surgery + EBRT/ADT 2,349 6.6 853 4.4 801 11.1 339 8.6 548 10.8 
EBRT alone 2,536 7.1 1,533 7.8 573 7.9 136 3.5 431 8.5 
EBRT + ADT 7,488 20.9 3,688 18.8 2,359 32.7 658 16.8 783 15.4 
ADT alone 3,116 8.7 965 4.9 487 6.8 1,116 28.4 356 7.0 
Systemic + ADT 630 1.8 71 0.4 37 0.5 450 11.5 72 1.4 
Systemic + EBRT (+/- ADT) 513 1.4 84 0.4 128 1.8 237 6.0 64 1.3 
Other treatment groups 5,709 15.9 2873 14.7 1257 17.4 680 17.3 899 17.7 
Age at survey 
<55 years 661 1.8 447 2.3 92 1.3 45 1.1 77 1.5 
55-64 years 5,594 15.6 3,366 17.2 1,026 14.2 473 12.1 729 14.3 
65-74 years 16,638 46.4 9,420 48.1 3,406 47.2 1,712 43.6 2,100 41.3 
75-84 years 11,082 30.9 5,670 28.9 2,391 33.2 1,326 33.8 1,695 33.3 
85+ years 1,842 5.1 696 3.6 294 4.1 369 9.4 483 9.5 
Unknown 6 0.02 0 0.0 0 0.0 0 0.0 6 0.1 
Socio-economic 
deprivation 
quintile 
1 - least deprived 9,408 26.3 5,128 26.2 1,802 25.0 962 24.5 1,516 29.8 
2 9,289 25.9 5,186 26.5 1,889 26.2 1,000 25.5 1,241 24.4 
3 7,381 20.6 4,082 20.8 1,504 20.9 869 22.1 926 18.2 
4 5,266 14.7 2,846 14.5 1,084 15.0 596 15.2 740 14.5 
5 - most deprived 3,620 10.1 1,955 10.0 786 10.9 421 10.7 458 9.0 
Unknown 859 2.4 402 2.1 144 2.0 77 2.0 236 4.6 
No. of other 
long-term 
conditions 
0 10,405 29.0 5,740 29.3 2,087 28.9 1,131 28.8 1,447 28.4 
1 12,527 35.0 6,910 35.3 2,594 36.0 1,316 33.5 1,707 33.5 
2 7,154 20.0 3,827 19.5 1,432 19.9 807 20.6 1,088 21.4 
3 3,174 8.9 1,708 8.7 605 8.4 391 10.0 470 9.2 
≥4 2,563 7.2 1,414 7.2 491 6.8 280 7.1 378 7.4 
EBRT: External beam radiotherapy; ADT: Androgen deprivation therapy; Systemic therapy includes chemotherapy/Abiraterone/Enzalutamide.  
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Table 2: Functional and HRQL outcomes in men diagnosed with prostate cancer 18-42 months previously 
 
  
EPIC-26 domain  
(adjusted mean score*: 100 = best possible function) 
EQ-5D dimension  
(adjusted % reporting any level of problem*) 
EQ-5D 
Overall HRQL* 
 Urinary 
incontinence 
Urinary 
irritation 
Bowel 
function 
Hormone 
function 
Sexual 
function Mobility  Self-care 
Usual 
activities 
Pain/ 
discomfort 
Anxiety/ 
depression 
≥1 problem 
(%) 
Mean SAH 
rating 
  n=31,827 n=29,274 n=30,861 n=31,746 n=32,525 n=35,411 n=35,470 n=35,416 n=35,349 n=35,310 n=34,769 n=35,003 
All men 82.6 85.9 88.9 79.9 24.0 33.8 11.5 36.5 41.7 33.0 63.2 76.3 
      
       
Stage             
I/II 82.9 86.0 89.6 83.6 28.5 29.7 9.8 32.0 38.9 31.0 59.8 77.4 
III 81.2 86.2 87.4 75.3 16.4 34.8 11.6 38.5 42.3 33.9 64.7 76.3 
IV 83.2 84.7 88.1 68.0 11.9 49.8 18.9 53.3 54.6 43.0 76.5 71.7 
 
     
       
Treatment             
AS 87.6 83.0 93.1 90.0 44.6 24.3 7.4 23.9 34.5 30.8 57.3 78.7 
WW 87.1 85.2 93.1 88.0 41.3 31.6 10.4 31.6 36.7 30.9 59.0 77.2 
Brachy alone 89.2 84.1 88.8 89.3 37.6 20.7 5.9 22.9 36.4 25.2 52.6 79.6 
Surg alone 73.5 90.0 93.4 89.6 22.1 23.9 7.6 29.1 33.5 27.3 54.6 79.5 
Surg + EBRT/ADT 73.1 86.1 86.2 76.9 14.9 34.0 11.6 40.0 42.9 35.5 66.1 76.0 
EBRT alone 86.7 86.1 86.2 80.7 25.6 32.8 10.2 33.4 41.2 28.4 59.7 77.6 
EBRT + ADT 86.8 85.5 84.4 72.2 19.1 34.4 10.7 38.0 44.6 34.3 64.8 76.2 
ADT alone 86.4 84.6 90.9 69.3 15.3 43.0 15.9 47.6 46.5 41.0 74.3 72.0 
Syst + ADT 86.2 84.6 90.7 66.9 11.5 55.1 19.5 59.3 57.2 46.4 81.8 70.4 
Syst + EBRT 85.1 83.4 83.8 66.2 12.4 59.5 25.5 62.2 61.7 45.6 82.4 68.3 
*Adjusted for age at survey, socio-economic deprivation and number of other long-term conditions. 
AS: Active surveillance; WW: Watchful waiting; Brachy: Brachytherapy; Surg: Surgery; EBRT: External beam radiotherapy; ADT: Androgen deprivation therapy; Syst: Systemic therapy 
(Chemotherapy/Abiraterone/Enzalutamide); SAH: Self-assessed health.  
Due to the large number of men included in the study, statistical significance can be achieved with only small differences in outcomes, and these may not be clinically relevant.  Results should 
be considered alongside previously estimated minimally important differences.  For EPIC-26: Urinary incontinence (6-9 points); Urinary irritation/obstruction (5-7 points); Bowel function (4-6 
points); Vitality/hormone function (4-6 points); Sexual function (10-12 points).  For EQ-5D Self-assessed health (7 points).  
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Table 3: Comparison of self-assessed health ratings in the LAPCD cohort and general 
population surveys (men aged 60 and over) 
  n Mean SAH 
LAPCD   
Stage I/II 18,055 77.8 
Stage III 6,792 76.6 
Stage IV 3,759 71.7 
Overall 33,370 76.5 
   
General population   
Northern Ireland, 20161 2,597 77.2 
Health Survey for England, 20122 1,016 74.2 
SAH: Self-assessed health 
1Northern Ireland General population survey (Donnelly et al. Urinary, bowel and sexual health in older men from 
Northern Ireland. BJU Int 2018. doi: 10.1111/bju.14182). 
2Health Survey for England 2012 (NHS Digital. Available from https://digital.nhs.uk/data-and-
information/publications/statistical/health-survey-for-england/health-survey-for-england-2012). 
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Figure 1: Urinary, bowel and vitality/hormone function in men diagnosed with prostate cancer 18-42 
months previously 
 
 
Figures represent predicted adjusted proportions (adjusted for age, socio-economic deprivation and no. of other long-term 
conditions)   
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Figure 2: Sexual function in men diagnosed with prostate cancer 18-42 months previously 
 
Figure 2a represents predicted adjusted proportions (adjusted for age, socio-economic deprivation and no. of other long-
term conditions)  
 
Figure 2b represents predicted adjusted proportions (adjusted for socio-economic deprivation and no. of other long-term 
conditions)   
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Figure 3: Use of interventions to improve sexual function by men diagnosed with prostate cancer 18-42 months previously 
 
Figures represent unadjusted proportions  
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Figure 4: Self-assessed health ratings in men diagnosed with prostate cancer 18-42 months 
previously 
 
 
 
Figures represent predicted adjusted mean scores (adjusted for socio-economic deprivation and no. of other long-term 
conditions)   
ADT: Androgen deprivation therapy 
Results should be considered alongside the previously estimated minimally important difference for EQ-5D Self-assessed 
health (7 points). 
